BRIEF-Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Reuters05-13

May 13 (Reuters) - Senti Biosciences Inc :

* SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA

* SENTI BIOSCIENCES INC: INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025

* SENTI BIOSCIENCES INC - INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435324246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-13 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435324246","market":"us","top_or_hot":-1,"title":"BRIEF-Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia","media":"Reuters","content":"<html><body><p>May 13 (Reuters) - Senti Biosciences Inc   :</p><p>   * SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA</p><p>   * SENTI BIOSCIENCES INC: INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025</p><p>   * SENTI BIOSCIENCES INC - INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-13 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 13 (Reuters) - Senti Biosciences Inc   :   * SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNTI","symbol_name":"Senti Biosciences, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2435324246","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435324246","pubTimestamp":1715602743,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 13  - Senti Biosciences Inc   :   * SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA   * SENTI BIOSCIENCES INC: INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025   * SENTI BIOSCIENCES INC - INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNTI":"Senti Biosciences, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"简介-Senti Bio宣布首名患者接受SENTI-202治疗复发或难治性恶性血液病（包括急性髓细胞白血病）的1期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":0.9},"content_text":"May 13 (Reuters) - Senti Biosciences Inc   :   * SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA   * SENTI BIOSCIENCES INC: INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025   * SENTI BIOSCIENCES INC - INITIAL CLINICAL EFFICACY DATA EXPECTED BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435324246"}